文献速递妇科

子宫内膜癌前哨淋巴结低体积转移的肿瘤学结局:国际多中心研究

Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study.
PubMed 文献 · Gynecol Oncol · 2021-07-15

该研究回顾性纳入22个中心247例子宫内膜癌伴前哨淋巴结低体积转移(≤2mm)患者,评估肿瘤学结局。中位随访无复发者29.6个月,4年无复发生存率为77.6%。多因素分析显示非子宫内膜样癌、淋巴血管间隙浸润和子宫浆膜侵犯是复发独立预测因素。

要点

  • 前哨淋巴结低体积转移患者4年无复发生存率为77.6%。
  • 非子宫内膜样癌、淋巴血管间隙浸润和子宫浆膜侵犯为复发独立危险因素。
  • 子宫内膜样G1仅ITC且无LVSI/USI者预后良好,或可免辅助治疗。

核心结论

  • 前哨淋巴结低体积转移患者中,非子宫内膜样癌、淋巴血管间隙浸润和子宫浆膜侵犯是复发独立危险因素。
  • 具有任一危险因素的患者预后较差,即使接受辅助治疗。
  • 子宫内膜样G1仅ITC且无LVSI/USI者预后良好,即使未接受辅助治疗。

研究设计与样本

  • 排除FIGO IV期、附件受累或辅助治疗未知者。
  • 132例为孤立肿瘤细胞,115例为微转移。

主要发现

  • 总体4年无复发生存率为77.6%(95%CI,70.2%-85.9%)。
  • 无复发患者中位随访29.6个月(四分位距,19.2-41.5)。
  • 47例子宫内膜样癌仅ITC且未接受辅助治疗者,4年无复发生存率为82.6%(95%CI,70.1%-97.2%)。
  • 18例子宫内膜样G1仅ITC、无LVSI、无USI且未接受辅助治疗者中,仅1例复发(中位随访24.8个月)。

临床怎么用

  • 对前哨淋巴结低体积转移患者,应评估非子宫内膜样癌、淋巴血管间隙浸润和子宫浆膜侵犯以分层复发风险。
  • 存在任一危险因素者预后较差,需考虑辅助治疗。
  • 子宫内膜样G1仅ITC且无LVSI/USI者预后良好,或可考虑省略辅助治疗,但需进一步验证。

局限性

  • 回顾性研究设计。
  • 部分亚组样本量较小(如18例),随访时间有限。
  • 需更多患者和更长随访评估低危亚组能否免辅助治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess oncologic outcomes in endometrial cancer patients with low-volume metastasis (LVM) in the sentinel lymph nodes (SLNs). METHODS: Patients with endometrial cancer and SLN-LVM (≤2 mm) from December 3, 2009, to December 31, 2018, were retrospectively identified from 22 centers worldwide. Patients with International Federation of Gynecology and Obstetrics (FIGO) stage IV, adnexal involvement, or unknown adjuvant therapy (ATx) were excluded. RESULTS: Of 247 patients included, 132 had isolated tumor cell (ITC) and 115 had micrometastasis (MM). Overall 4-year recurrence-free survival (RFS) was 77.6% (95% CI, 70.2%-85.9%); median follow-up for patients without recurrence was 29.6 (interquartile range, 19.2-41.5) months. At multivariate analysis, Non-endometrioid (NE) (HR, 5.00; 95% CI, 2.50-9.99; P < .001), lymphovascular space invasion (LVSI) (HR, 3.26; 95% CI, 1.45-7.31; P = .004), and uterine serosal invasion (USI) (HR, 3.70; 95% CI, 1.44-9.54; P = .007) were independent predictors of recurrence. Among 47 endometrioid ITC patients without ATx, 4-year RFS was 82.6% (95% CI, 70.1%-97.2). Considering 18 ITC patients with endometrioid grade 1 disease, without LVSI, USI, or ATx, only 1 had recurrence (median follow-up, 24.8 months). CONCLUSIONS: In patients with SLN-LVM, NE, LVSI, and USI were independent risk factors for recurrence. Patients with any risk factor had poor prognosis, even when receiving ATx. Patients with ITC and grade 1 endometrioid disease (no LVSI/USI) had favorable prognosis, even without ATx. Further analysis (with more patients and longer follow-up) is needed to assess whether ATx can be withheld in this low-risk subgroup.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ghoniem K, Larish AM, Dinoi G, et al. Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study. Gynecol Oncol. 2021. PMID: 34274133. doi:10.1016/j.ygyno.2021.06.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。